Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences

    NOVATO, Calif., Oct. 29 /CNW/ -- Raptor Pharmaceuticals Corp. (OTC
Bulletin Board: RPTP), today announced that senior management will present a
corporate overview and clinical pipeline updates at two upcoming healthcare
investor conferences:
    --  The 7th Annual BIO Investor Forum, to be held October 29-31, 2008 at
        the Palace Hotel in San Francisco, CA. Raptor's presentation will take
        place on Wednesday, October 29 at 4:45pm ET (1:45pm PT) in Telegraph
        Hill. A live audio webcast of the presentation will be available at

    --  The Rodman & Renshaw 10th Annual Healthcare Conference, to be held
        November 10-12, 2008 at New York Palace Hotel in New York, NY.
        presentation will take place on Tuesday, November 11 at 9:30am ET
        (6:30am PT) in Holmes II (4th floor). A live audio webcast of the
        presentation will be available at

    Both webcasts will be archived for 30 days and accessible through the
investor relations section of Raptor's website at www.raptorpharma.com.

    For more information on BIO Investor Forum conference please visit:

    For more information on Rodman & Renshaw's 10th Annual Healthcare
Conference please visit: http://www.rodmanandrenshaw.com/conferences

    About Raptor Pharmaceuticals Corp.
    Raptor Pharmaceuticals Corp. ("Raptor") is a publicly traded
biotechnology company dedicated to speeding the delivery of new treatment
options to patients by working to improve existing therapeutics through the
application of highly specialized drug targeting platforms and formulation
expertise. Raptor focuses on underserved patient populations where it believes
it may have the greatest impact. Raptor is involved in clinical development of
its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate
in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"),
Huntington's Disease and Batten Disease, and its ConviviaTM product candidate
in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical programs
Raptor bioengineers novel drug candidates and drug-targeting platforms derived
from the human receptor-associated protein ("RAP") and related proteins which
are designed to target cancer, neurodegenerative disorders and infectious
diseases. Raptor's preclinical programs include HepTideTM, WntTideTM and

    For additional information, please visit www.raptorpharma.com.

    This document contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements
relate to future events or our future results of operation or future financial
performance, including, but not limited to the following statements:  Raptor's
ability to develop any of its preclinical and clinical drug product
candidates. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause our actual
results to be materially different from these forward-looking statements.
Factors which may significantly change or prevent our forward looking
statements from fruition include that we may be unsuccessful in developing any
products or acquiring products; that our technology may not be validated as we
progress further and our methods may not be accepted by the scientific
community; that we are unable to retain or attract key employees whose
knowledge is essential to the development of our products; that unforeseen
scientific difficulties develop with our process; that our patents are not
sufficient to protect essential aspects of our technology; that competitors
may invent better technology; that our products may not work as well as hoped
or worse, that our products may harm recipients; and that we may not be able
to raise sufficient funds for development or working capital when we require
it. As well, our products may never develop into useful products and even if
they do, they may not be approved for sale to the public. We caution readers
not to place undue reliance on any such forward-looking statements, which
speak only as of the date they were made. Certain of these risks,
uncertainties, and other factors are described in greater detail in our
filings from time to time with the Securities and Exchange Commission (the
"SEC"), which we strongly urge you to read and consider, including our
Registration Statement on Form S-1 that was declared effective on August 7,
2008; our annual report on Form 10-KSB filed with the SEC on November 14,
2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all of which are
available free of charge on the SEC's web site at http://www.sec.gov.
Subsequent written and oral forward-looking statements attributable to us or
to persons acting on our behalf are expressly qualified in their entirety by
the cautionary statements set forth in our reports filed with the SEC. We
expressly disclaim any intent or obligation to update any forward-looking

    For more information, please contact:
        The Ruth Group
        Sara Ephraim (investors)
        (646) 536-7002

        Janine McCargo (media)
        (646) 536-7033


For further information:

For further information: Investors, Sara Ephraim, +1-646-536-7002,
sephraim@theruthgroup.com, or Media, Janine McCargo, +1-646-536-7033,
jmccargo@theruthgroup.com, both of The Ruth Group Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890